Bio-Reference

The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.

Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.

The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.